anandamide has been researched along with Autistic-Disorder* in 5 studies
1 review(s) available for anandamide and Autistic-Disorder
Article | Year |
---|---|
Towards the discovery of novel T-type calcium channel blockers.
Despite their presence in many tissues and their potential implication in various disease states, low-voltage activated T-type calcium channels (T-channels) have only recently become targets of interest. Unfortunately, the lack of selective T-channel blockers has hampered further characterisation of these channels. The recent availability of cloned T-channels, the Ca(V)3 proteins, facilitates identification of novel T-channel blockers. Also, studies performed in knockout animals have fostered novel interest. Selective inhibition of T-channels may have clinical importance in cardiovascular diseases, some forms of epilepsy, sleep disorders, pain and possibly cancer. This review focuses on novel research approaches to discover potent and selective T-channel modulators. These molecules may be potential drugs for treating human diseases, as well as important tools to decipher the physiological role of these channels. Topics: Analgesics; Animals; Anticonvulsants; Arachidonic Acids; Autistic Disorder; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cardiovascular Agents; Cardiovascular Diseases; Cations; Drug Design; Endocannabinoids; Epilepsy; Humans; Mice; Mice, Knockout; Polyunsaturated Alkamides; Scorpion Venoms; Sleep Disorders, Intrinsic | 2007 |
4 other study(ies) available for anandamide and Autistic-Disorder
Article | Year |
---|---|
Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats.
Autism spectrum disorder (ASD) has a multifactorial etiology. Major efforts are underway to understand the neurobiological bases of ASD and to develop efficacious treatment strategies. Recently, the use of cannabinoid compounds in children with neurodevelopmental disorders including ASD has received increasing attention. Beyond anecdotal reports of efficacy, however, there is limited current evidence supporting such an intervention and the clinical studies currently available have intrinsic limitations that make the interpretation of the findings challenging. Furthermore, as the mechanisms underlying the beneficial effects of cannabinoid compounds in neurodevelopmental disorders are still largely unknown, the use of drugs targeting the endocannabinoid system remains controversial. Here, we studied the role of endocannabinoid neurotransmission in the autistic-like traits displayed by the recently validated Fmr1- Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Cannabinoids; Endocannabinoids; Fragile X Mental Retardation Protein; Models, Genetic; Phenotype; Polyunsaturated Alkamides; Rats; Receptor, Cannabinoid, CB1 | 2023 |
These findings are the first empirical human data to translate preclinical rodent findings to confirm a link between plasma anandamide concentrations in children with ASD. Although preliminary, these data suggest that impaired anandamide signaling may be involved in the pathophysiology of ASD. Topics: Arachidonic Acids; Autistic Disorder; Biomarkers; Cannabinoid Receptor Agonists; Case-Control Studies; Child; Child, Preschool; Endocannabinoids; Female; Humans; Male; Polyunsaturated Alkamides | 2018 |
Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling.
Autism spectrum disorder (ASD) is more commonly diagnosed in males than in females. Prenatal exposure to the antiepileptic drug valproic acid (VPA) is an environmental risk factor of ASD. Male rats prenatally exposed to VPA show socio-emotional autistic-like dysfunctions that have been related to changes in the activity of the endocannabinoid anandamide. Here, we have investigated if prenatal VPA induced sex-specific autistic endophenotypes involving anandamide signalling.. We studied sex-specific differences in the ASD-like socio-emotional, cognitive and repetitive symptoms displayed during development of Wistar rats of both sexes, prenatally exposed to VPA. The involvement of anandamide was followed by Western blotting of cannabinoid CB. Female rats were less vulnerable to the deleterious effects of prenatal VPA exposure on social communication, emotional reactivity and cognitive performance than male rats. Conversely, as observed in male rats, prenatal VPA exposure induced selective deficits in social play behaviour and stereotypies in the female rat offspring. At the neurochemical level, prenatal VPA exposure altered phosphorylation of CB. These findings highlight sexually dimorphic consequences of prenatal VPA exposure that may be related to sex-specific effects of VPA on endocannabinoid neurotransmission in the course of development and introduce a new therapeutic target for reversing autistic-like symptoms in both sexes. Topics: Animals; Anticonvulsants; Arachidonic Acids; Autistic Disorder; Behavior, Animal; Endocannabinoids; Female; Hydrolysis; Locomotion; Male; Phenotype; Phosphorylation; Polyunsaturated Alkamides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Sex Factors; Signal Transduction; Valproic Acid | 2018 |
Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid.
Autism spectrum disorders are a group of neurodevelopmental disorders characterised by impaired social interaction, deficits in communication and repetitive stereotyped behaviours. The endocannabinoid system plays an important role in modulating emotionality and social responding, however there have been a paucity of studies investigating this system in autistic animal models. This study investigated the effect of inhibiting fatty acid amide hydrolyase (FAAH), the anandamide catabolic enzyme, on behavioural responding in the valproic acid (VPA) rat model of autism. Male rats prenatally exposed to VPA exhibit an autistic-like behavioural phenotype exemplified as thermal hypoalgesia, reduced social and exploratory behaviour, and enhanced repetitive behaviour. Systemic administration of the FAAH inhibitor PF3845 (10mg/kg) attenuated the deficit in social behaviour observed in VPA exposed male animals without altering nociceptive, repetitive or exploratory behaviour. In comparison, female VPA exposed rats displayed enhanced repetitive and reduced exploratory behaviour, but no change in social behaviour or thermal nociceptive responding. PF3845 did not alter social, repetitive or thermal nociceptive responding, but reduced exploratory behaviour in a social context in VPA-, but not saline-, exposed females. These data indicate that FAAH inhibition elicits sexual dimorphic effects on behavioural responding in VPA exposed rodents, and support an important role for FAAH in the regulation of social behavioural deficits in autistic males. Topics: Amidohydrolases; Animals; Arachidonic Acids; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Endocannabinoids; Female; Male; Piperidines; Polyunsaturated Alkamides; Pyridines; Rats; Rats, Sprague-Dawley; Sex Characteristics; Social Behavior; Valproic Acid | 2016 |